US 12220409
Roflumilast formulations with an improved pharmacokinetic profile
granted A61KA61K31/44A61K45/06
Quick answer
US patent 12220409 (Roflumilast formulations with an improved pharmacokinetic profile) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/10, A61K47/24